Announced Thu, 25 Jun · 22:32 IST
USFDA Pre-License Inspection at Bachupally biologics facility ends with 7 Form 483 observations
Regulatory & Legal View source PDF
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.7%1-day move
₹1349.50
prior close
₹1388.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.1+1.2+0.6+1.1+0.7-0.8-0.4+1.6+1.1+0.1-9.5———
Up moveDown movePending
AI summary
Dr Reddys told stock exchanges that the USFDA completed a Pre-License Inspection at its biologics manufacturing facility in Bachupally, Hyderabad from June 16 to June 25, 2026. The inspection ended with a Form 483 carrying seven observations, which the company will address within the stipulated timeline. This follows earlier inspections disclosed on October 12, 2023 and September 13, 2025.
Likely market impact
Form 483 observations are routine and addressable, but repeat inspections at the same facility may raise concerns about potential approval delays.